| Literature DB >> 32351908 |
Bagher Larijani1, Parisa Goodarzi2, Moloud Payab3, Sepideh Alavi-Moghadam4, Fakher Rahim5, Nikoo Bana6, Mina Abedi4, Maryam Arabi4, Hossein Adibi7, Kambiz Gilany8,9, Babak Arjmand4,6.
Abstract
Diabetes with a broad spectrum of complications has become a global epidemic metabolic disorder. Till now, several pharmaceutical and non-pharmaceutical therapeutic approaches were applied for its treatment. Cell-based therapies have become promising methods for diabetes treatment. Better understanding of diabetes pathogenesis and identification of its specific biomarkers along with evaluation of different treatments efficacy, can be possible by clarification of specific metabolic modifications during the diabetes progression. Subsequently, metabolomics technology can support this goal as an effective tool. The present review tried to show how metabolomics quantifications can be useful for diabetic monitoring before and after cell therapy. Cell therapy is an alternative approach to achieve diabetes treatments goals including insulin resistance amelioration, insulin independence reparation, and control of glycemia. OMICs approaches provide a comprehensive insight into the molecular mechanisms of cells features and functional mechanism of their genomics, transcriptomics, proteomics, and metabolomics profile which can be useful for their therapeutic application. As a modern technology for the detection and analysis of metabolites in biological samples, metabolomica can identify many of the metabolic and molecular pathways associated with diabetes and its following complications.Entities:
Keywords: Cell-based therapy; diabetes mellitus; metabolic diseases; metabolic pathways; metabolomics
Year: 2019 PMID: 32351908 PMCID: PMC7175613 DOI: 10.22088/IJMCM.BUMS.8.2.41
Source DB: PubMed Journal: Int J Mol Cell Med ISSN: 2251-9637
Advantages and disadvantages of diabetes medicines
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| Metformin | Reducing hepatic glucose, fasting glycemia, | Weight loss | Reducing hepatic glucose output through inhibition of gluconeogenesis | ( |
|
| Glibenclamie (Daonil), Gliclazide (Glizid( | Secreting insulin Decreasing glycemia, | Weight gain | Increasing insulin secretion regulated by ATP-sensitive potassium channels | ( |
|
| Glitazones, Pioglitazone | Using glucose by increasing the insulin sensitivity in muscle, fat, and liver tissues | Weight gain | Increasing insulin sensitivity by binding to peroxisome proliferator-activated receptors, improving blood glucose levels by preserving pancreatic beta-cell function | ( |
|
| Decreasing hemogolobin A1C, | Weight gain | Reducing glucose concentration by increasing glucose uptake or reducing glucose production | ( |
Fig. 1Metabolomics in cell therapy. The level of metabolites can be changed after transplantation. Hence, metabolomics can explain the efficacy of treatment by monitoring the metabolites before and after cell therapy via targeted and non-targeted methods (59).